文献速递核素与放射性配体治疗肿瘤 PET/CT

[203/212Pb]Pb-VMT-α-NET作为靶向α放疗的新型诊疗一体化药物:首次临床经验

[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy-first clinical experience.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-09

本研究对12例进展性转移性胃肠胰神经内分泌肿瘤(GEP-NET)1-3级患者行[203Pb]Pb-VMT-α-NET诊断显像,合格者接受单剂[212Pb]Pb-VMT-α-NET治疗(1.2 MBq/kg体重),并与[68Ga]Ga-DOTATATE PET比较。未见高级别不良反应,治疗后3个月内所有患者影像与肿瘤标志物稳定;作者认为耐受性良好且疗效有前景,需进一步研究多周期治疗。

要点

  • [203Pb]Pb-VMT-α-NET显像未见高级别不良反应,瘤内摄取高但病灶间异质,与[68Ga]Ga-DOTATATE PET可比。
  • 单剂[212Pb]Pb-VMT-α-NET治疗(1.2 MBq/kg体重)所有患者耐受良好,无高级别或严重不良反应。
  • 治疗后3个月内所有患者影像与肿瘤标志物稳定;作者认为需在更大样本中研究多周期治疗的耐受性与疗效。

局限性

  • 作者指出需进一步研究在更大患者人群中多周期治疗的耐受性与疗效。
  • 本研究为单剂治疗,未评估多周期治疗的耐受性与疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 203/212Pb is a promising theranostic isotope pair for targeted alpha therapy (TAT) of neuroendocrine tumors (NET). VMT-α-NET is a novel SSTR2 targeting peptide that can be labeled with both isotopes. The aim of this work was to perform first clinical investigations of [203/212Pb]Pb-VMT-α-NET regarding imaging, biokinetics, tolerability and response. METHODS: 12 patients (9 m/3 w; mean age 71, range 60-84) with progressive metastatic GEP-NET grade 1-3 received diagnostic imaging with [203Pb]Pb-VMT-α-NET (4.9 MBq/kg bw) up to 24 h p.i. (whole body & SPECT/CT) and, if eligible, a single dose of [212Pb]Pb-VMT-α-NET therapy (1.2 MBq/kg bw) after exhaustion of all current therapies (including [177Lu]Lu- & [225Ac]Ac-DOTATATE), and post-treatment imaging with [212Pb]Pb-VMT-α-NET up to 24 h p.i. (whole body & SPECT/CT). Clinical and laboratory parameters were monitored. A visual and quantitative comparison was made with [68 Ga]Ga-DOTATATE PET scans before and 3 months after therapy. RESULTS: No high-grade adverse effects were observed in all patients evaluated with [203Pb]Pb-VMT-α-NET. All patients showed an initial high, but lesion-dependent heterogeneous intratumoral accumulation, comparable to [68 Ga]Ga-DOTATATE PET. Treatment with [212Pb]Pb-VMT-α-NET was also well tolerated by all patients without high-grade or serious adverse side effects. Post-therapeutic PET scans and tumor marker controls showed stable findings in all patients up to 3 months after treatment. CONCLUSION: Imaging with [203Pb]Pb-VMT-α-NET followed by a single dose of [212Pb]Pb-VMT-α-NET appears to be well tolerated with promising efficacy, even in a heterogenous and heavily pretreated patient population. Further studies are warranted to examine tolerability and efficacy over multiple treatment cycles in larger patient populations.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Michler E, Kästner D, Pretze M, et al. [203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy-first clinical experience. Eur J Nucl Med Mol Imaging. 2025. PMID: 40202686. doi:10.1007/s00259-025-07269-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。